Asunaprevir

Asunaprevir
Names
IUPAC name
3-Methyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-L-prolinamide
Other names
BMS-650032
Identifiers
630420-16-5 YesY
ChEMBL ChEMBL2105735
ChemSpider 17235944
Jmol interactive 3D Image
KEGG D10093 YesY
PubChem 16076883
Properties
C35H46ClN5O9S
Molar mass 748.29 g·mol−1
Pharmacology
ATC code J05AE15
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Asunaprevir (formerly BMS-650032, brand name in Japan and Russia[1] Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It is undergoing development by Bristol-Myers Squibb and is currently in Phase III clinical trials.[2]

Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.[3]

Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.[4][5][6]

See also

References

This article is issued from Wikipedia - version of the Thursday, February 18, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.